159 related articles for article (PubMed ID: 19822140)
1. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
5. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
6. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
7. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis.
Svensson PA; Olson FJ; Hägg DA; Ryndel M; Wiklund O; Karlström L; Hulthe J; Carlsson LM; Fagerberg B
Int J Mol Med; 2008 Oct; 22(4):459-64. PubMed ID: 18813852
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
Ostrowski SR; Ullum H; Goka BQ; Høyer-Hansen G; Obeng-Adjei G; Pedersen BK; Akanmori BD; Kurtzhals JA
J Infect Dis; 2005 Apr; 191(8):1331-41. PubMed ID: 15776381
[TBL] [Abstract][Full Text] [Related]
13. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J
Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
18. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
19. Is serum pregnancy-associated plasma protein A really a potential marker of atherosclerotic carotid plaque stability?
Heider P; Pfäffle N; Pelisek J; Wildgruber M; Poppert H; Rudelius M; Eckstein HH
Eur J Vasc Endovasc Surg; 2010 Jun; 39(6):668-75. PubMed ID: 20399126
[TBL] [Abstract][Full Text] [Related]
20. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
